Get instant savings up to 75%
Download the Free PrescriptionDrugs.com Discount Drug Card
Redeem for instant savings up to 75% on name brand
& generic prescription drugs
Accepted at over 60,000 pharmacies nationwide
The FDA has decided to add drugs references warning labels that detail the potential risks of heart disease and diabetes to patients who use prostate cancer gonadotropin-releasing hormone (GnRH) agonists. In addition to the drug’s generic classification, GnRH drugs are sold as brand names Eligard,, Lupron, Synarel, Trelstar, Vantas, and Zoladex in the U.S
GnRH are a class of drugs that work by suppressing testosterone production. Testosterone production is known to accelerate the growth of prostate cancer. GnRH drugs are typically prescribed to patients in advanced stages of the disease.
Drugs References for Class GnRH Drugs
The October 20, 2010 decision to add warning labels comes after the analysis of a preliminary study which links GnRH agonists to increased risks of conditions such as diabetes, heart attack and sudden death. Although risks are still perceived as relatively low, physicians are being asked by the FDA to monitor and evaluate patients for these diseases as well as periodically measure blood glucose levels.
Changes to the labels will include updates to the warnings and precautions sections about new and potential risks. The FDA has also asked that physicians carefully evaluate and screen patients prior to prescribing GnRH class drugs.
Prostate cancer is the most common non-skin related cancer in the U.S., affecting an estimated 1in 6 men, taking the lives of an estimated 32,000 annually.
Patients who use prostate cancer drugs to control the disease will now find adequate prescription drugs references on their medication informing them of the risks.